Clovis Oncology and Foundation Medicine have joined forces to develop an in vitro diagnostic to identify, using biomarkers, patients that may respond to a PARP inhibitor of Clovis' that is in development, the companies announced. The companies aim to uncover genetic mutations associated with defective DNA repair, other than BRCA mutations, and other targets for rucaparib. "This continues our commitment to developing targeted therapies with companion diagnostics to identify the patients most likely to benefit from our therapeutics," says Patrick Mahaffy, president and CEO of Clovis Oncology, in a statement. "Foundation Medicine's leadership in next generation sequencing and genomic analysis make them an ideal partner to work with us on our rucaparib program." The Sample's sister publication GenomeWeb Daily News has more on this collaboration.